RxDoctor Payments Data

Kimberly Gudzune, MD

Gastroenterology · Baltimore, MDNPI 1942344361

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $43,014 of the $59,547 with a category attached, or 72.2%. 6 manufacturers reported payments, led by Eli Lilly at 55.7% of the total. Reporting peaked in 2023 at $32,534 and has fallen 89.9% since, to $3,287 in 2024. Among gastroenterology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$59,547in general payments, 2019–2025

Across 98 payments — averaging $607.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$33K
  • Novo Nordisk$17K
  • Lilly USA, LLC$9K
  • AbbVie$118
  • Boston Scientific$79
  • Kvk-tech, Inc.$50
$87,649in research payments, 2019–2025

Across 5 payments — averaging $17,530 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk$81K
  • Eli Lilly$6K

What the payments were for

  • Consulting fees$43,01472%
  • Speaking & faculty fees$5,2889%
  • Travel & lodging$7,16412%
  • Food & beverage$2,1364%
  • Education$1,9453%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly38$33,147
Novo Nordisk14$17,211
Lilly USA, LLC37$8,943
AbbVie1$118
Boston Scientific1$79
Kvk-tech, Inc.7$50

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,547 in reported general payments places this provider in the 90th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$5,517
Medicare patients
18
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide13$22,437
OzempicSemaglutide12$10,658
Bupropion XlBupropion Hcl24$728
Naltrexone Hcl12$490
Topiramate13$41
Losartan Potassium13$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$8,943$22,43713 claims
Novo NordiskOzempic$17,211$10,65812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →